Metraipolis › archive › dc_2fcfabbf9e69

Impact of National Drug Price Negotiation policy on the innovation performance of biopharmaceutical industry in China — Europe PMC PMID:41262702

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41262702
DOI
10.3389/fpubh.2025.1705030
License (as archived)
solo-consultazione
Archived
2026-11-08T19:25:40.330Z
SHA-256 of the archived text
bc0164aaa574edce6483a17b25ba15c6ce87d8978a848cf8970c649972fe1890
Stable URL of this page
https://metraipolis.com/documento/dc_2fcfabbf9e69

How to cite

Impact of National Drug Price Negotiation policy on the innovation performance of biopharmaceutical industry in China — Europe PMC PMID:41262702 — Europe PMC (en), https://europepmc.org/article/MED/41262702 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2fcfabbf9e69 (Metraipolis archive dc_2fcfabbf9e69, sha256 bc0164aaa574edce6483a17b25ba15c6ce87d8978a848cf8970c649972fe1890)
BibTeX
@misc{dc2fcfabbf9e69,
  title = {Impact of National Drug Price Negotiation policy on the innovation performance of biopharmaceutical industry in China — Europe PMC PMID:41262702},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41262702},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2fcfabbf9e69; sha256 bc0164aaa574edce6483a17b25ba15c6ce87d8978a848cf8970c649972fe1890},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41262702. Agents can read the archived copy with the MCP tool read_document.